How does the November 2025 preclinical data on oral semaglutide affect competition in obesity treatments?

Rani Therapeutics' November 2025 preclinical data on oral semaglutide (RT-116), presented at ObesityWeek® 2025, indicates a significant development in the obesity treatment landscape. The data demonstrated that oral semaglutide delivered via the RaniPill® (RT-116) achieved comparable bioavailability, pharmacokinetics, and weight loss to subcutaneous administration.1 This builds upon earlier preclinical findings from February 2025 that also showed similar efficacy and good tolerability for RT-116.2

This preclinical success suggests that Rani's proprietary RaniPill® capsule platform could effectively enable the oral delivery of biologics like semaglutide, which are typically administered via injection.2 The potential implications for competition in obesity treatments include:

• Enhanced Patient Convenience and Adherence: Oral administration is generally preferred by patients over injections, which could lead to improved adherence and broader market adoption if clinical trials confirm these preclinical findings.3 This could challenge the market dominance of injectable GLP-1 receptor agonists.
• Differentiation from Existing Oral Options: While an oral semaglutide (Rybelsus) is already available, Rani's approach aims to deliver the biologic directly into the intestine, potentially offering a different pharmacokinetic profile or higher bioavailability without the strict administration requirements of current oral tablets. The reported comparability to subcutaneous administration in preclinical studies is a key differentiator.1
• Market Expansion: An effective, convenient oral biologic could open up new segments of the GLP-1 market, particularly in regions where cold-chain storage for injectables is challenging or where patient preference strongly favors non-injectable routes.4
• Increased Competition in Oral GLP-1s: The obesity treatment market, projected to exceed $120 billion by 2030, is already seeing intense activity with other oral GLP-1s in development, such as Eli Lilly's small molecule orforglipron.3 Rani's progress adds another strong contender, specifically targeting the oral delivery of a biologic semaglutide.

This preclinical data, while promising, represents an early stage of development. Successful translation into human clinical trials will be crucial to validate these findings and assess the true competitive impact.

Compare the reported weight loss percentages of RT-116 in preclinical studies against published preclinical or early clinical data for other oral GLP-1 agonists in development.

The question regarding the reported weight loss percentages of Rani Therapeutics' RT-116 in preclinical studies, compared to other oral GLP-1 agonists, highlights a crucial aspect of competitive analysis in the obesity treatment space.

Rani Therapeutics has consistently reported that its oral semaglutide (RT-116), delivered via the RaniPill® capsule, demonstrated comparable bioavailability, pharmacokinetics, and weight loss to subcutaneous administration of semaglutide in preclinical studies.1 While specific weight loss percentages for RT-116 itself in these preclinical studies are not explicitly detailed in the provided filings, the emphasis is on its equivalence to injectable semaglutide. For context, clinical data for injectable semaglutide (e.g., Wegovy) has shown significant weight reduction, with some studies indicating median total body weight loss of around 20.9% in patients on GLP-1 therapy.2

In comparison, other oral GLP-1 agonists in development have reported the following:

• Eli Lilly's Orforglipron (oral small molecule GLP-1 RA):
• Phase 3 Attain-2 trial: Achieved an average weight loss of 10.5% at 72 weeks (vs. 2.2% for placebo).3
• Phase 3 Attain-1 trial: Showed an average weight loss of 12.4% at 72 weeks (vs. 0.9% for placebo).4
• Phase 3 Achieve 1 trial: Demonstrated a 7.9% average weight reduction (or 6.3% placebo-adjusted) at 40 weeks.5
• Structure Therapeutics' Aleniglipron (oral small molecule GLP-1 RA):
• Phase 2b ACCESS study: Reported a placebo-adjusted mean weight loss of 11.3% at 36 weeks with a 120 mg dose.6
• Exploratory ACCESS II study: Observed a placebo-adjusted mean weight loss of up to 15.3% at 36 weeks with a 240 mg dose.6

It is important to note that direct comparisons between preclinical data (like Rani's RT-116) and clinical trial data (like Eli Lilly's and Structure Therapeutics') should be made with caution due to differences in study design, duration, subject populations (animal models vs. humans), and methodologies. However, the consistent reporting of "comparable weight loss" for RT-116 to subcutaneous semaglutide in preclinical settings suggests a promising efficacy profile that warrants further clinical investigation. The reported percentages for other oral candidates highlight the high bar for efficacy in this competitive market.

Analyze the reported tolerability and safety profiles of RT-116 and other oral GLP-1 agonists, as these factors significantly influence patient adherence and market adoption.